Skip to content
Study details
Enrolling now

A Study of SPY072 in Rheumatic Disease

Spyre Therapeutics, Inc.
NCT IDNCT07148414ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

285

Study length

about 2.6 years

Ages

18+

Locations

13 sites in AZ, CA, FL +2

About this study

This trial is testing a treatment called SPY072 compared to a placebo in adults with rheumatic diseases. The goal is to see if SPY072 is effective and safe for this condition.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Placebo
  • 2.Take SPY002-072
PhasePhase 2
Primary goalAxial Spondyloarthritis: Change from baseline in Ankylosing Spondylitis Disease Activity Score (ADAS)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low4%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Axial Spondyloarthritis: Change from baseline in Ankylosing Spondylitis Disease Activity Score (ADAS), Rheumatoid Arthritis: Change from baseline in Disease Activity Score in 28 joints (c-reactive protein) (DAS-CRP)

Secondary: Psoriatic Arthritis: Change from baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA)

Body systems

Dermatology, Immune, Musculoskeletal